P&F acquires heart-valve startup AVVie to target untreated mitral disease
What's the deal? P&F Products & Features GmbHDealroom has a profile for this one. Try Dealroom → has acquired AVVie GmbHDealroom has a profile for this one. Try Dealroom →, a structural heart technology startup founded by cardiac surgeon Werner MohlDealroom has a profile for this one. Try Dealroom →. Financial terms were not disclosed.
What each side brings: AVVie developed the AngelValve Augmentation System, a transcatheter platform for treating mitral valve disease in patients with limited or no options. P&F contributes global capabilities in product development, clinical and regulatory affairs, manufacturing, and commercialisation.
Why now? More than 13 million people across Europe and the US have mitral regurgitation, a condition in which blood leaks backward into the heart's left atrium. Yet no more than 5% of patients with moderate to severe disease currently receive treatment.
What's the endgame? P&F says combining AVVie's R&D infrastructure and intellectual property with its own capabilities will accelerate innovation and shorten development timelines. The company frames the deal as a step toward becoming a global leader in structural heart therapy.
What they're saying: The acquisition "reflects our continued commitment to advancing breakthrough structural heart therapies," said Katharina KissDealroom has a profile for this one. Try Dealroom →, chief executive officer of P&F. Chief operating officer Siegfried Einhellig added that the two sides bring together "outstanding engineering talent and proven development capabilities."
The signal: The deal points to continued consolidation in structural heart, where larger players with regulatory and commercial reach are absorbing startups to close a wide gap between patients who need treatment and those who get it.
Read more: InfoMed News
Image credit: Generated with Gemini
